CN111788229A - Csf1r结合剂 - Google Patents

Csf1r结合剂 Download PDF

Info

Publication number
CN111788229A
CN111788229A CN201980015847.8A CN201980015847A CN111788229A CN 111788229 A CN111788229 A CN 111788229A CN 201980015847 A CN201980015847 A CN 201980015847A CN 111788229 A CN111788229 A CN 111788229A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
region amino
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980015847.8A
Other languages
English (en)
Chinese (zh)
Inventor
W·J·J·芬雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Superman 12 Ltd
Original Assignee
Superman 12 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Superman 12 Ltd filed Critical Superman 12 Ltd
Publication of CN111788229A publication Critical patent/CN111788229A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980015847.8A 2018-02-28 2019-02-28 Csf1r结合剂 Pending CN111788229A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1803226.8A GB201803226D0 (en) 2018-02-28 2018-02-28 CSF1R Binding agents
GB1803226.8 2018-02-28
GBGB1810226.9A GB201810226D0 (en) 2018-02-28 2018-06-21 CSF1R binding agents
GB1810226.9 2018-06-21
GB1819045.4 2018-11-22
GBGB1819045.4A GB201819045D0 (en) 2018-02-28 2018-11-22 Csf1r binding agents
PCT/EP2019/055077 WO2019166596A1 (en) 2018-02-28 2019-02-28 Csf1r binding agents

Publications (1)

Publication Number Publication Date
CN111788229A true CN111788229A (zh) 2020-10-16

Family

ID=61903334

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980015847.8A Pending CN111788229A (zh) 2018-02-28 2019-02-28 Csf1r结合剂

Country Status (10)

Country Link
US (1) US11655300B2 (https=)
EP (1) EP3759137A1 (https=)
JP (1) JP2021514654A (https=)
CN (1) CN111788229A (https=)
AU (1) AU2019228110A1 (https=)
CA (1) CA3091307A1 (https=)
GB (3) GB201803226D0 (https=)
IL (1) IL276914A (https=)
SG (1) SG11202007837RA (https=)
WO (1) WO2019166596A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112472790A (zh) * 2020-12-25 2021-03-12 同济大学 小白蛋白的抑制剂在制备预防治疗肥胖以及肥胖导致的疾病产品中的用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023547499A (ja) * 2020-11-06 2023-11-10 ノバルティス アーゲー 抗体Ｆｃ変異体
CN119019548B (zh) * 2022-07-05 2025-06-24 东莞市朋志生物科技有限公司 抗甲型流感病毒抗体、检测甲型流感病毒的试剂和试剂盒

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009112245A1 (en) * 2008-03-14 2009-09-17 Transgene S.A. Antibody against the csf-1 r
WO2011123381A1 (en) * 2010-04-01 2011-10-06 Imclone Llc Antibodies against csf-1r
WO2011140249A2 (en) * 2010-05-04 2011-11-10 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
CN104093740A (zh) * 2012-02-06 2014-10-08 弗·哈夫曼-拉罗切有限公司 使用csf1r抑制剂的组合物和方法
WO2015028455A1 (en) * 2013-08-30 2015-03-05 Ucb Biopharma Sprl Antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009112245A1 (en) * 2008-03-14 2009-09-17 Transgene S.A. Antibody against the csf-1 r
WO2011123381A1 (en) * 2010-04-01 2011-10-06 Imclone Llc Antibodies against csf-1r
WO2011140249A2 (en) * 2010-05-04 2011-11-10 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
CN104093740A (zh) * 2012-02-06 2014-10-08 弗·哈夫曼-拉罗切有限公司 使用csf1r抑制剂的组合物和方法
WO2015028455A1 (en) * 2013-08-30 2015-03-05 Ucb Biopharma Sprl Antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PAPADOPOULOS ET AL: "First-in-human study of AMG 820,a monoclonal anti-colony-stimulating factor 1 receptor antibody,in patients with advanced solid tumors", 《CLINICAL CANCER RESEARCH》 *
RIES ET AL: "Targeting tumor-associated macrophages with anti-csf1r antibofy reveals a strategy for cancer therapy", 《CANCER CELL》 *
ZAMARIN ET AL: "Upregulation of PD-L1 in tumor microenvironment is a resistance mechanism for oncolytic virus immunotherapy", 《JOURNAL FOR IMMUNOTHERAPY OF CANCER》 *
钱莲芳等: "集落刺激因子1及其受体的单抗对人肝癌细胞在裸鼠体内生长的抑制作用", 《肿瘤》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112472790A (zh) * 2020-12-25 2021-03-12 同济大学 小白蛋白的抑制剂在制备预防治疗肥胖以及肥胖导致的疾病产品中的用途
CN112472790B (zh) * 2020-12-25 2022-12-20 同济大学 小白蛋白的抑制剂在制备预防治疗肥胖以及肥胖导致的疾病产品中的用途

Also Published As

Publication number Publication date
CA3091307A1 (en) 2019-09-06
EP3759137A1 (en) 2021-01-06
WO2019166596A1 (en) 2019-09-06
IL276914A (en) 2020-10-29
GB201819045D0 (en) 2019-01-09
US20210301026A1 (en) 2021-09-30
GB201803226D0 (en) 2018-04-11
JP2021514654A (ja) 2021-06-17
SG11202007837RA (en) 2020-09-29
GB201810226D0 (en) 2018-08-08
US11655300B2 (en) 2023-05-23
AU2019228110A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
US12173067B2 (en) C-KIT antibodies and method for treating cancer with such
KR102929571B1 (ko) Cd47 결합제
US12415861B2 (en) Anti C-MET antibodies
EP3762419A1 (en) Pd1 binding agents
JP7689116B2 (ja) Ｐｄ１およびｖｅｇｆｒ２二重結合剤
CN111819201A (zh) Pd1结合剂
US10975165B2 (en) De-immunised anti-ERBB3 antibodies
US11655300B2 (en) Colony stimulating factor 1 receptor (CSF1R) antibodies and immunoconjugates thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201016